RedHill Biopharma

RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company focused on gastrointestinal and infectious diseases

[RedHill Biopharma @RedHillBio]

#RDHL’s #opaganib receives @FDA rare pediatric disease designation for neuroblastoma, with potential for #PriorityReviewVoucher. Adds to prior #orphandrugdesignation. $RDHL PR: https://t.co/LYWQxhBAmU

[RedHill Biopharma @RedHillBio]

$RDHL has commenced recognition and enforcement proceedings in #Korea for the $11 million #NewYork #SupremeCourt final judgment in favor of #RDHL against #Kukbo. Press release: https://t.co/M63d67g3Ik

[RedHill Biopharma @RedHillBio]

#RDHL advancing #opaganib options for #Ebola biodefense platforms, incl. @WHO’s SOLIDARITY CORE clinical trial platform & pharma collaborations, amid rapidly evolving #Bundibugyo #EVD outbreak, which has no approved medications or vaccines. $RDHL PR: https://t.co/szELNeszK0

[RedHill Biopharma @RedHillBio]

#RDHL’s RHB-204 comparable MAP killing efficacy to RHB-104, with lower doses. Key step in RHB-204’s FDA-guided path to potential groundbreaking MAP-related approach to #Crohns. Multiple FDA designations, possible PRV and regulatory exclusivities. $RDHL PR: https://t.co/S3ynsaSoM3

[RedHill Biopharma @RedHillBio]

$RDHL FY2025: Tenacity, transactions & traction - transformed #Talicia business with $4M Cumberland $CPIX deal, RHB-102 deal worth up to $60M with @Hyloris, positive equity at end 2025 & R&D advances in #Crohn’s, #oncology & #GLP1 GI effects. #RDHL PR: https://t.co/htoUvXJnYi

[RedHill Biopharma @RedHillBio]

New preclinical data presented @AACR #AACR2026 annual meeting shows positive effects of #RDHL’s #opaganib as potential add-on therapy in models of #neuroblastoma (#NB) and triple-negative #breastcancer (#TNBC). $RDHL PR: https://t.co/gXFWAHsdiO

[RedHill Biopharma @RedHillBio]

#RDHL announces the start of joint U.S. commercialization of #Talicia with Cumberland ($CPIX), with full sales and operational launch commencing to support accelerated market penetration and expanded reach. $RDHL PR: https://t.co/gXj7Km2500

[RedHill Biopharma @RedHillBio]

#RDHL progress for #RHB-102 (#Bekinda®) in multiple GI indications, including development via FDA 505(b)(2) route, as a once-daily pill for #GLP1 GI side effects – no. 1 reason patients stop therapy, limiting $billion GLP-1 market growth. $RDHL PR: https://t.co/2oFRVPOHAG

[RedHill Biopharma @RedHillBio]

#RDHL’s opaganib plus venetoclax halves number of venetoclax-resistant #CLL #cancer cells in vivo compared to control – potential as add-on therapy to $2.5B blockbuster in emerging venetoclax-resistant CLL therapeutic challenge. $RDHL PR: https://t.co/3o1HFkcRLi @GamberaleRomina

[RedHill Biopharma @RedHillBio]

$RDHL successfully regains compliance with the @Nasdaq stockholders’ equity requirement. #RDHL PR: https://t.co/XFw3u4kUw9

[RedHill Biopharma @RedHillBio]

$RDHL’s $10.5 million New York Supreme Court judgment win now final for enforcement. No further appeal permissible. 9% annual statutory interest continues to accrue on award. #RDHL PR: https://t.co/zy3jqBJoJG

[RedHill Biopharma @RedHillBio]

$RDHL secures $4 million strategic investment & U.S. co-commercialization partnership with $CPIX (Cumberland) for a 30% stake in #RDHL’s #Talicia business & shared net revenues - set to accelerate sales growth & deliver significant efficiencies. PR: https://t.co/fD92pjQ6C3

[RedHill Biopharma @RedHillBio]

#RDHL is deeply saddened by the loss of our dear friend & SAB member, Prof. Thomas Borody. He will be greatly missed, but his legacy lives on - 1st to formulate today’s gold standard triple therapy for #HPylori & paving the way for a potential game-changing #Crohnsdisease therapy

[RedHill Biopharma @RedHillBio]

$RDHL signs new $1.8 million + royalties Middle East deal for #Talicia - speeds entry to new Middle East markets. #RDHL receives $0.5M guaranteed payments + minimum of $1.3M in near-term milestone payments, and net sales royalties. PR: https://t.co/chyFEaaJRN

[RedHill Biopharma @RedHillBio]

$RDHL wins New York Supreme Court appeal, upholding $10 million summary judgment against Kukbo, unequivocally dismissing Kukbo’s defense and stating that RedHill had fulfilled all obligations. #RDHL PR: https://t.co/jSFqipoqQO

[RedHill Biopharma @RedHillBio]

$RDHL 1H25: Bayer-supported #opaganib prostate cancer & groundbreaking #RHB-204 Crohn’s studies advancing, #Talicia growth – numbers & territories, up to $60 million #RHB-102 to @Hyloris deal, net revenue up 60% & gross profit doubled. #RDHL PR: https://t.co/1szWyt2M8s

[RedHill Biopharma @RedHillBio]

$RDHL awarded $1.8 million in legal costs and expenses by #NewYorkSupremeCourt, in addition to RedHill’s prior $8.25 million #NewYork #SupremeCourt summary judgment win. Awards include 9% ongoing statutory interest accrual. #RDHL PR: https://t.co/yMllzgcQZI

[RedHill Biopharma @RedHillBio]

#RDHL has received $1.1 million in first ex-U.S. #Talicia licensing payments. $RDHL PR: https://t.co/AcmgG9T5PS

[RedHill Biopharma @RedHillBio]

Positive #FDA feedback for #RDHL’s #RHB204 approval path for #Crohnsdisease. Groundbreaking: 1st in a MAP+ only patient group & cutting-edge MAP testing enabling smaller sample size, lower cost & faster completion; Non-dilutive funding planned. $RDHL PR: https://t.co/uqUzw8thBW

[RedHill Biopharma @RedHillBio]

@anzuP @Bayer @ramsay Apologies for the incorrect tag @ANZUPtrials

[RedHill Biopharma @RedHillBio]

Recruitment initiated for unique @ANZUP led, @Bayer & @Ramsay supported, #RDHL P2 opaganib + darolutamide study in patients with advanced prostate cancer using novel precision medicine patient selection companion lipid biomarker test (PCPro ). $RDHL PR: https://t.co/QhH16OHOiy